Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
about
Nuclear Receptor Regulation of Aquaporin-2 in the KidneyThe Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular DiseasesPhysiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidneyE-type prostanoid receptor 4 (EP4) in disease and therapyA novel therapeutic effect of statins on nephrogenic diabetes insipidusProtein trafficking defects in inherited kidney diseasesAquaporins: important but elusive drug targets.Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice.Differential, phosphorylation dependent trafficking of AQP2 in LLC-PK1 cellsHigh-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentrationAquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus-update and epidemiology.Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.New insights into the dynamic regulation of water and acid-base balance by renal epithelial cells.Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus.Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.A mouse strain less responsive to dioxin-induced prostaglandin E2 synthesis is resistant to the onset of neonatal hydronephrosis.Lithium: a versatile tool for understanding renal physiology.Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway.Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct.Congenital nephrogenic diabetes insipidus: the current state of affairs.Inherited secondary nephrogenic diabetes insipidus: concentrating on humans.Urinary concentration: different ways to open and close the tap.Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.The vasopressin type 2 receptor and prostaglandin receptors EP2 and EP4 can increase aquaporin-2 plasma membrane targeting through a cAMP-independent pathway.Molecular mechanisms regulating aquaporin-2 in kidney collecting duct.Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: An Update.Development and Diseases of the Collecting Duct System.PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.The EP3 receptor regulates water excretion in response to high salt intake.Antidiuretic Action of Collecting Duct (Pro)Renin Receptor Downstream of Vasopressin and PGE2 Receptor EP4.Prorenin Receptor, a Necessary Component in Urine Concentration Mechanism.mPGES-1 deletion potentiates urine concentrating capability after water deprivation.Excretion of urinary exosomal AQP2 in rats is regulated by vasopressin and urinary pH.PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct.Prostaglandin E2 in the Regulation of Water Transport in Renal Collecting Ducts.Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.Diabetes Insipidus.Molecular Biology of Aquaporins.Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus.AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
P2860
Q26740554-E674F37E-BFAD-4051-94FB-FD021D1E3B11Q26768170-FFA854BD-511D-474E-BB7C-362F608184B6Q26771378-4BBBEE98-6A96-4D83-B02B-5BD036D4EA9BQ26851156-18D2CC8C-836C-4A0B-8258-13C793AE3A2FQ27005638-442C9D29-D6AA-4E7D-9832-813016990377Q27012909-420F306B-D591-42CF-AAD0-65BE8BE47610Q33792739-C29CA31B-53D3-4EF2-8868-948D20430479Q33840550-021C24F3-3D98-4C20-809D-C970A3366639Q34189252-C8B6B446-C8F4-4ECC-B905-2F52D0B01A83Q34295359-80C1BEAA-0DA4-4BF3-9722-9D7C9425657BQ35452558-9EE953A9-BDF4-4D7E-A42F-31097C30C363Q35845853-1147F8F4-0E84-470E-834E-F488F052F71CQ35993741-85336B8E-A766-49F6-A9D7-7430F1C310BEQ36138589-7A32BE13-07B2-4EBD-BA90-0D748CD6EFB9Q36724058-9B1EDB7B-FB2F-41E3-A374-03E21F4B9CA9Q36801701-C2BEF11E-D580-4E97-8E5C-451DFB4FC067Q36836247-43A9B31B-F4F8-4331-96B8-4CCDDB4D4AC0Q37465201-EF2EB5CF-F7AB-4B78-AD1B-7AE850AA8CD1Q37609062-8F6EC1C9-017A-48A1-82D6-E25032C73848Q37994652-3DABE0FF-939A-405E-8115-CA0C4B0CF870Q38077934-2B2B5A58-7AE0-4AFB-B75B-C716A3AB0915Q38111968-BDE7F679-382B-413F-9BC1-2E7E28344818Q38528569-B69656F9-909C-4502-BD00-94439E0569C7Q38734391-4A0CDC2A-855F-486B-8054-774ADBBB198DQ38985544-26DBD83E-005C-49DC-8039-6D9C55D5BA1AQ39158847-4FFC6E55-AF8A-4363-940A-77046C1F07D0Q39242443-11F669FC-A50C-4FCE-8F86-3CDE4BD3204DQ39904422-AB430537-7307-408B-868F-6D1BF114E439Q41630785-2BCD4BE4-70F0-4CE3-BA8D-68876478AD36Q41645466-6C519D9C-C65F-4681-9820-EDFFC9795D0EQ42389546-E92724D8-6974-4668-9529-3E751AC6E033Q42538078-2ADBDC88-3821-49EF-B5BE-23DED988A162Q45805566-BB90F92A-79C2-4D08-80E7-D076DBB0349AQ47291983-727468BC-767F-4641-A7D4-3651680496A7Q47351317-0EC80675-E878-49B4-A12C-59A033A3D8AFQ47802729-A5C130B3-D905-4955-9D2A-4B309E967545Q51112288-DD71D4A8-F598-4A42-BC72-42CE4C5AB40FQ51112320-DADDA77F-B084-4BBD-A436-EFD90E32C8EFQ52686527-8F686378-6835-4466-9DC1-A4F67DDF707EQ52691158-5E1F5A69-7CC3-4381-8A47-821D404DDDC9
P2860
Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@ast
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@en
type
label
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@ast
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@en
prefLabel
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@ast
Vasopressin-independent target ...... ephrogenic diabetes insipidus.
@en
P2860
P50
P356
P1476
Vasopressin-independent target ...... nephrogenic diabetes insipidus
@en
P2093
Hanne B Moeller
P2860
P304
12949-12954
P356
10.1073/PNAS.1104691108
P407
P577
2011-07-18T00:00:00Z